Pharmaceuticals – SRK Analytics

Cipla Secures US FDA Approval for Generic Advair Diskus Across All Strengths

Indian pharmaceutical major Cipla Limited has secured final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for generic Advair Diskus. The regulatory clearance…

Prasenjit Bhowmik July 28, 2026

Business Insights

FDA Advisory Panel Endorses Broader Peptide Access, Igniting Concerns Over Compounding Pharmacy Boom

A Food and Drug Administration (FDA) advisory panel voted this week to endorse expanded access to therapeutic peptides through compounding pharmacies, a decision that health experts warn could spark an…

Prasenjit Bhowmik July 25, 2026

Emerging Market

Eli Lilly Targets 2027 Approval for Next-Generation Triple-Agonist Obesity Drug Retatrutide

Eli Lilly plans to seek approval for its next-generation obesity drug retatrutide by 2027 following highly successful late-stage clinical trials.

Prasenjit Bhowmik July 24, 2026

Business Insights

Indian Pharma Sector Pivots as US Evaluates Steep Tariffs on Generic Drug Imports

Discover how Indian drugmakers are adapting to potential US tariffs on generic imports while maintaining their global lead in affordable healthcare.

Prasenjit Bhowmik July 24, 2026

Economy

The Silent Crisis: Why Counterfeit and Substandard Drugs Persist in India’s Supply Chain

Discover why counterfeit and substandard drugs still plague Indias medicine supply chain and how regulatory gaps threaten public health.

Prasenjit Bhowmik July 20, 2026

Market

Cipla’s Strategic Outlook: Navigating Growth in the Global Pharmaceutical Landscape

As global demand for affordable healthcare continues to escalate, Mumbai-based pharmaceutical giant Cipla Limited is positioning itself for a pivotal three-year growth trajectory. With rising exports and a robust pipeline…

Prasenjit Bhowmik July 3, 2026

Emerging Market

Medicare Expands Coverage to Include Obesity Medications for Seniors

Medicare now covers obesity medications like Wegovy for seniors with heart-related risks, expanding access to vital chronic weight management treatment.

Prasenjit Bhowmik June 30, 2026

Business Insights

Jubilant Pharmova Subsidiary Secures Tentative USFDA Nod for Pantoprazole Oral Suspension

Jubilant Generics' tentative USFDA approval for Pantoprazole Oral Suspension marks a key milestone, paving the way for future market entry in 2026.

Prasenjit Bhowmik June 28, 2026

Business Insights

Bajaj Healthcare Secures Landmark SEC Recommendation for Cenobamate in India

Regulatory Milestone for Epilepsy TreatmentBajaj Healthcare Ltd. has become the first pharmaceutical company in India to receive a formal recommendation from the Subject Expert Committee (SEC) for the manufacturing and…

Prasenjit Bhowmik June 27, 2026